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Temporal lobeMicroRNAs (miRNAs) are small non-coding RNAs that post-transcriptionally control the expression of their
target genes via RNA interference. There is increasing evidence that expression of miRNAs is dysregulated in
neuronal disorders, including epilepsy, a chronic neurological disorder characterized by spontaneous recurrent
seizures. Mesial temporal lobe epilepsy (MTLE) is a common type of focal epilepsy in which disease-induced
abnormalities of hippocampal neurogenesis in the subgranular zone as well as gliosis and neuronal cell loss in
the cornu ammonis area are reported. We hypothesized that in MTLE altered miRNA-mediated regulation of
target genes could be involved in hippocampal cell remodeling. A miRNA screen was performed in hippocampal
focal and non-focal brain tissue samples obtained from the temporal neocortex (both n = 8) of MTLE patients.
Out of 215 detected miRNAs, two were differentially expressed (hsa-miR-34c-5p: mean increase of 5.7 fold
(p = 0.014), hsa-miR-212-3p: mean decrease of 76.9% (p = 0.0014)). After in-silico target gene analysis and
ﬁltering, reporter gene assays conﬁrmed RNA interference for hsa-miR-34c-5p with 3′-UTR sequences of
GABRA3, GRM7 and GABBR2 and for hsa-miR-212-3p with 3′-UTR sequences of SOX11, MECP2, ADCY1 and
ABCG2. Reporter gene assays with mutated 3′-UTR sequences of the transcription factor SOX11 identiﬁed two
different binding sites for hsa-miR-212-3p and its primary transcript partner hsa-miR-132-3p. Additionally,
therewas an inverse time-dependent expression of Sox11 andmiR-212-3p aswell asmiR-132-3p in rat neonatal
cortical neurons. Transfection of neurons with anti-miRs for miR-212-3p and miR-132-3p suggest that both
miRNAs work synergistically to control Sox11 expression. Taken together, these results suggest that differential
miRNA expression in neurons could contribute to an altered function of the transcription factor SOX11 and other
genes in the setting of epilepsy, resulting not only in impaired neural differentiation, but also in imbalanced
neuronal excitability and accelerated drug export.
© 2015 Elsevier Inc. All rights reserved.Introduction
Epilepsy is a common chronic neurological disorder affecting more
than 50million people of all ages worldwide (Sisodiya, 2007). The neu-
ronal hyperexcitabilty associated with seizures may be explained by anal and Clinical Pharmacology,
nold-Heller-Str. 3, Bldg. 30, D-
S. Haenisch).
ect.com).imbalance in excitatory and inhibitory signal transmission. However,
the cellular and molecular mechanisms underlying increased suscepti-
bility to recurrent seizures are not well understood. Mesial temporal
lobe epilepsy (MTLE) is a common type of focal epilepsy often associat-
ed with pharmacoresistance and a histopathological ﬁnding of mesial
temporal sclerosis (MTS) (Blumcke et al., 2007; Engel, 2001). Histopath-
ological ﬁndings in a rat MTLE model and in human hippocampal spec-
imens have demonstrated an increase in neurogenesis of dentate
granule cells accompanied by a dispersed dentate granule cell layer
and the ectopic location of granule cells in the hilus after acute seizures
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contribute to excitatory circuitry in the hilus and CA3 region. In contrast,
in the chronic phase of epilepsy with spontaneous recurrent seizures
and signs of gliosis and neuronal cell loss in the cornu ammonis area,
the number of neuronal stem cells (NSCs) seems not to change dramat-
ically. However, the correct differentiation of NSCprogenies intomature
neurons appears to be impaired (Hattiangady and Shetty, 2008; Kuruba
et al., 2009), potentially leading to areas of increased excitability that
contribute to the development, maintenance and progression of
epilepsy.
MicroRNAs (miRNAs) are small non-coding RNAs that post-
transcriptionally ﬁne-tune the expression of their target genes by inter-
fering with the mRNA 3′-UTR region, resulting in mRNA degradation or
inhibition of protein translation. miRNAs are involved in many impor-
tant cellular processes including proliferation, differentiation, andmain-
tenance of tissue speciﬁcity. The process of adult neurogenesis is
associated with a miRNA-controlled sequence of altered expression of
speciﬁc transcription factors and other proteins (Faigle and Song,
2013; Liu et al., 2010; Szulwach et al., 2010). Moreover, there is increas-
ing evidence that expression of miRNAs is dysregulated in neuronal dis-
orders, including Alzheimer's disease, depression, schizophrenia and
bipolar disorder (Jin et al., 2013). Recent reports from screening studies
in animal epilepsymodels and from human specimens ofMTLE patients
show that miRNA expression is also altered in epilepsy (Dogini et al.,
2013; Jimenez-Mateos and Henshall, 2013). Furthermore, epilepsy-
dependent alterations in miRNA expression change between the acute
post-seizure phase and the chronic, often intractable phase of spontane-
ous recurrent seizures (Bot et al., 2013; Song et al., 2011).
The current study is based on the hypothesis that hippocampal
neuronal reorganization in the chronic phase of MTLE is associated
with altered miRNA-mediated regulation of target genes predispos-
ing the brain to recurrent epileptic seizures. After screening
genome-wide miRNA expression in hippocampal focal and non-
focal brain tissue from the temporal neocortex of MTLE patients
who underwent temporal lobectomy, a reporter-gene assay was
used to functionally investigate the interaction between dysregulat-
ed miRNAs and predicted target genes potentially involved in hippo-
campal cellular remodeling during epileptogenesis. Bioinformatic
ﬁltering for potential target genes included a hypothesis-free as
well as a phenotype-guided approach. Candidate miRNAs and their
functionally conﬁrmed target genes identiﬁed in this study imply
that differential hippocampal miRNA expression could contribute
to altered function of several genes in the chronic stage of MTLE,
resulting not only in impaired neural differentiation, but also in im-
balanced neuronal excitability and accelerated drug export. More-
over, the results suggest that certain miRNAs act synergistically to
control the expression of their target gene, emphasizing the com-
plexity of miRNA networks in epilepsy.
Material and methods
Human tissue material
Eight hippocampal focal and eight non-focal brain tissue samples
obtained from the temporal neocortex of 10 MTLE patients (six
males and four females, mean age: 37.3 +/−11.5 years), who
underwent temporal lobectomy were screened for miRNA expres-
sion. The study protocol was approved by Committee on Human Re-
search (CHR) at University of California, San Francisco, and informed
consent was obtained from all participants. Demographic data, diag-
nosis, histopathological ﬁndings and history of pharmacotherapy are
summarized in Table 1.
Paraformaldehyde-ﬁxed, parafﬁn-embedded tissue slides of
hippocampus and frontal cortex obtained from autopsies of eight indi-
viduals (four males and four females, mean age: 52.4 +/− 5.9 years)
without neurological disorder were investigated for hsa-miR-212-3pexpression. This investigation was approved by the ethics committee
of the Medical Faculty of the University of Greifswald, Germany
(BB43/09).
miRNA isolation and miRNA screen in human brain tissue of MTLE patients
After homogenization of frozen tissue specimens ofMTLE patients on
dry ice, total RNA was isolated using a mirVana™ PARIS™ Kit (Ambion
by Life Technologies, Austin, TX, USA). Reverse transcription of 200 ng
of total RNA per samplewas performed using a TaqMan®MicroRNA Re-
verse TranscriptionKit andmiRNA speciﬁc RT primer pools (Megaplex™
Primer Pools, Human Pools Set v3.0, consisting of Megaplex™ RT
Primers, Human Pool A v2.1 and Pool B v3.0, Applied Biosystems by
Life Technologies, Foster City, CA, USA). Reverse transcription was
followed by a subsequent pre-ampliﬁcation step using a TaqMan® Pre-
Amp Master Mix (Applied Biosystems) and pre-ampliﬁcation primer
pools (Megaplex™ PreAmp Primers, Human Pool A v2.1 and Pool B
v3.0, Applied Biosystems). Resulting cDNAs were diluted 1:4 in 0.1X
TE (1X TE-Buffer: Tris (10 mM), EDTA (1 mM), pH = 8.0, Ambion)
and then loaded together with TaqMan® Universal Master Mix II, no
UNG (Applied Biosystems) on low density arrays (ﬁnal dilution 1:400,
TaqMan® Array Human MicroRNA A + B Cards Set v3.0, Applied
Biosystems) in a volume of 100 μl per port. Quantitative real-time PCR
was run on anABI prism 7900HT (Applied Biosystems). All described re-
actions were performed according to a standard protocol provided by
the manufacturer. NormFinder software (Andersen et al., 2004) identi-
ﬁed RNU48 as themost stably expressed housekeeping gene in both tis-
sue types. miRNA expression was quantiﬁed as 2-ΔCt, where ΔCt is the
difference in Ct values between the gene of interest and RNU48.
Principal component analysis and identiﬁcation of differently expressed
miRNAs
Only those miRNAs detected in all 16 brain tissue samples were
included in the ﬁnal comparison between focal hippocampal and non-
focal temporal neocortical tissue. Visualization of miRNA expression
data was done by heatmap and by Principal Component Analysis
(PCA) in the statistical computing environment R/Bioconductor
(Gentleman et al., 2004; R Development Core Team, 2010) (Fig. 1).
Comparison between both tissue types was conducted by Mann–Whit-
ney U test and multiple testing correction was performed using
Benjamini and Hochberg False Discovery rate (FDR) (Benjamini and
Hochberg, 1995) in R (Gentleman et al., 2004; R Development Core
Team, 2010)with theHTqPCR package (Dvinge and Bertone, 2009). Dif-
ferentially expressed miRNAs having a p-value ≤0.02 and a log2-
transformed fold change ≥2.0 were considered relevant for further
investigation.
Conﬁrmation of selected candidate miRNA expression
Reverse transcription of 20 ng of total RNA, obtained from above
mentioned frozen tissue specimens of MTLE patients, was conducted
using respective RT primer pools and a TaqMan® MicroRNA Reverse
Transcription Kit. Conﬁrmation of array candidate miRNA expression
was performed without a pre-ampliﬁcation step using individual
TaqMan® MicroRNA assays (hsa-miR-34c-5p: Assay ID 000428, hsa-
miR-212-3p: Assay ID 000515, hsa-miR-221: Assay ID 000524,
RNU48: Assay ID 001006) and TaqMan® Universal Master Mix II, no
UNG (all reagents purchased from Applied Biosystems). Total RNA
was isolated from paraformaldehyde-ﬁxed, parafﬁn-embedded tissue
slides of autopsies using the RecoverAll™ Total Nucleic Acid Isolation
Kit (Ambion). After reverse transcription and a subsequent pre-
ampliﬁcation step, expression of hsa-miR-212-3p and RNU48 was
measured using respective TaqMan® MicroRNA assays. Both reactions,
eitherwith orwithout a pre-ampliﬁcation step,were conducted accord-
ing to a protocol provided by the manufacturer.
Table 1
Demographic data, diagnosis, pharmacotherapy and type of examined brain tissue of MTLE patients.
Patient Gender Age at
surgery
(years)
Age at onset
of
disease
Type of examined
brain
tissue
Diagnosis /Histopathology Anticonvulsant
at surgery prior
1 female 30 10 months Hippocampus Medically refractory epilepsy with temporal lobe
focus;
MTS conﬁrmed
CBZ VAP, TGB, PBT
2 female 46 2 years Hippocampus Medically refractory epilepsy with temporal lobe
focus;
MTS conﬁrmed
ZNS, DVP DVP, TGB
3 male 62 41 years Temporal neocortex Medically refractory epilepsy with temporal lobe
focus;
MTS conﬁrmed
CBZ DVP, ZNS, LEV, PHT, LTG, TPR, CLZ
4 female 23 5-6 years Temporal neocortex Medically refractory epilepsy with temporal lobe
focus;
signs of MTS
LTG, GBP PHT, CBZ, PBT, DVP, ZNS, GBP
5 male 34 24 years Hippocampus,
temporal neocortex
Medically refractory epilepsy with temporal lobe
focus;
no signs of MTS
DVP, CBZ PHT, GBP, CBZ, DVP
6 female 27 25 years Hippocampus,
temporal neocortex
Medically refractory epilepsy with temporal lobe
focus;
signs of MTS
LTG, OXC LEV, PHT,
unknown multiple other
anticonvulsants
7 male 35 18 months Hippocampus,
temporal neocortex
Medically refractory epilepsy with temporal lobe
focus,
MTS conﬁrmed
OXC, LEV,
LZP
LTG,
unknown multiple other
anticonvulsants
8 male 51 42 years Hippocampus,
temporal neocortex
Medically refractory epilepsy with temporal lobe
focus;
MTS conﬁrmed
DVP, CBZ PHT, DVP, CBZ
9 male 36 9 months Hippocampus,
temporal neocortex
Medically refractory epilepsy with temporal lobe
focus;
MTS conﬁrmed
CBZ, PGB,
LZP
PBT VAP, LTG, LEV, LZP
10 male 29 early
childhood
Hippocampus,
temporal neocortex
Medically refractory epilepsy with temporal lobe
focus;
signs of MTS
DVP, OXC unknown multiple other
anticonvulsants
MTS:mesial temporal sclerosis, CBZ: carbamazepine, CLZ: clonazepam, DVP: divalproex, GBP: gabapentin, LTG: lamotrigine, LEV: levetiracetam, LZP: lorazepam, OXC: oxcarbazepine, PBT:
phenobarbital, PHT: phenytoin, PGB: pregabaline, TGB: tiagabine, TPR: topiramate, VAP: valproic acid, ZNS: zonisamide.
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Two approaches were conducted in parallel to extract genes pre-
dicted to be targeted by selected candidate miRNAs. One approach
(hypothesis-guided) accounted for ATP-binding cassette (ABC)
transporters known to be involved in drug resistance (ABCB1,
ABCC1, ABCC2, ABCC4, ABCG2), a phenomenon often observed in
the chronic stage of MTLE (Engel, 2001), as well as for genes related
to GABAergic and glutamatergic signal transmission. ABC trans-
porters were tested for predicted miRNA/mRNA interaction using
four different prediction databases, namely TargetScan release 5.2
(Grimson et al., 2007), RNAHybrid (Rehmsmeier et al., 2004), PicTar
(Krek et al., 2005) and miRanda (Betel et al., 2008). GABAergic and
glutamatergic signal transmission-related target genes were extract-
ed from gene lists generated using the GOmir software application
(Roubelakis et al., 2009), which refers to those four different
databases.
The second approach was hypothesis-generating. Genes were se-
lected which were predicted by GOmir (Roubelakis et al., 2009) to be
targeted by at least three of the six most highly expressed miRNAs
(top 3% of all detected miRNAs in the examined brain samples) and ad-
ditionally by one of the selected differentially expressed candidate
miRNAs. The intention underlying this ﬁltering approachwas that high-
ly expressedmiRNAs in brainmay play an important role inmaintaining
optimal expression of genes that are critical for normal neuronal
function.Cell culture
Human hepatoblastoma HepG2 cells (DMSZ, Braunschweig,
Germany) were cultured in RPMI 1640 medium (GE Healthcare, PAALaboratories, Pasching, Austria) supplemented with 10% fetal bovine
serum (FBS Superior, Biochrome, Berlin, Germany) and 50 units/ml
penicillin and 50 μg/ml streptomycin (Gibco by lifetechnologies, Carls-
bad, CA, USA) at 37 °C in a 5% CO2 atmosphere.Cloning of reporter gene plasmids and site directed mutagenesis
Reporter gene plasmids were generated to conﬁrm miRNA/mRNA-
3′-UTR interference between selected miRNAs and putative target
genes. 3′-UTR sequences containing the predicted binding site for the
respective candidate miRNA were ampliﬁed from human genomic
DNA using forward primers containing a PmeI restriction site and
reverse primers containing a XbaI (GABRA3: XhoI) restriction site
(Table 2) and subsequently inserted into the pmirGLO vector (Promega,
Madison, WI, USA). Table 2 shows the positions of the inserted 3′-UTR
sequences and location of the predicted miRNA binding site. A total of
14 plasmids were generated for nine putative target genes since some
of the 3′-UTR sequences were predicted to have more than one binding
site for the respective candidate miRNA. Predicted target sequences for
hsa-miR-212-3p were subsequently subcloned into the psiCHECK™2
vector (Promega), since co-transfection of pmiRGLO vector and pre-
miR-212-3p showed strong off-target effects. To facilitate ligation of
the inserts into the correct 5′- to 3′-direction downstreamof the report-
er sequence, the multiple cloning site of the psiCHECK™2 vector had to
be slightly modiﬁed. For exact procedure see supplementary methods.
The resulting plasmid DNA is fromnowon referred to as psicheck2S vec-
tor. T4 DNA ligase was purchased from Invitrogen by Life Technologies
(Carlsbad, CA, USA) and Antarctic Phosphatase and restriction enzymes
were purchased from NewEngland Biolabs (Frankfurt, Germany). Plas-
mid DNAwas ampliﬁed in DH5α competent E. coli cells. The correctness
of inserted target sequences was veriﬁed by capillary sequencing of
Fig. 1. Array-based miRNA screen and target gene ﬁltering strategies. A) PCA: blue circles, hippocampal focal tissues; red circles, temporal neocortical non-focal tissues. Heatmap: 215
miRNAs detected in both tissue types were sorted in terms of increasing overall median expression values (red high, green low expression level). B) Volcano plot: Comparison of 215
miRNAs between 8 focal hippocampal and 8 non-focal temporal neocortical tissues with a Mann–WhitneyU test and subsequent correction for multiple testing revealed sixteen miRNAs
having an unadjustedp-value≤0.05. For detailed information about p-values, FDR adjusted p-values (q-values) andmean fold changes (FC) see table to the left of Venndiagram. Themost
prominent candidates (hsa-miR-34c-5p, hsa–miR-212-3p and hsa-miR-221-3p) showed a p-value≤0.02 and a log2 transformed fold change≥2.0. C) Venndiagram showing the results of
target gene ﬁltering for hsa-miR-34c-5p and hsa–miR-212-3p. Both a hypothesis-guided and a hypothesis-generating approach were used as described in the Materials and Methods
section.
130 S. Haenisch et al. / Neurobiology of Disease 77 (2015) 127–140plasmid DNA (GATC Biotech, Konstanz, Germany), using the respective
forward or reverse primers shown in Table 2.
To conﬁrm the exact locations of predicted hsa-miR-212-3p and
hsa-miR-132-3p miRNA binding sites in SOX11-3′-UTR, mutations
were introduced into the target sequence of the SOX11-V2 plasmid by
site-directed mutagenesis and appropriate mutagenesis primers; the
distal wild type sequence ACCTTTTTTTGAATTGACTGTTT (predicted by
TargetScan 5.2 and miRanda) and the proximal wild type sequence
AGGCAGTGCGCTGGAGGATGA (predicted by RNAHybrid)were changed
into ACCTTTTTTTCTATTCTATCCTT and AGACAGGGCGTACAGGGATGA,
respectively (nucleotides of seed sequence are in bold, mutated nucleo-
tides are italicized). A plasmid carrying both mutated sequences was
also generated. Each mutagenesis PCR reaction was performed by
using 5 ng of wildtype SOX11-V2 plasmid DNA as template and the
KAPAHiFi™ PCR Kit (PeqLab, Biotechnologie GmbH, Erlangen,
Germany) according to standard recommendations of the manufactur-
er. Dpn-I (New England Biolabs) restriction digestion was immediately
conducted for 1 hour at 37 °C. The resulting mutant plasmids were
named SOX11-V2-mut-TS, SOX11-V2-mut-RHy and SOX11-V2-mut-
dko. Mutated target sequences were veriﬁed by capillary sequencing
of plasmid DNA (IKMB, Kiel, Germany), using the respective forward
(FW-SOX11-V2) or reverse primers (RV-SOX11-V2) as shown in
Table 2. All described primers and oligonucleotides were purchased
from Sigma-Aldrich (Munich, Germany).
Reporter gene assays with mutated SOX11-V2 plasmids, co-
transfected with pre-miR-212-3p, Pre-miR-132-3p or pre-miR-NC, at a
concentration of 2.5 nM each, were performed as described below.Transient transfection with precursor-miRNAs and reporter gene assays
The interaction between predicted target mRNA-3′-UTR
sequences and selected candidate miRNAs was evaluated in HepG2
cells, chosen for their putative non-brain like endogenous miRNA
expression proﬁle. Cells were reverse transfected in 96-well plates
by covering 20 μl of transfection complex with 80 μl of cell suspen-
sion (120,000 cells/ml) per well. For generation of transfection com-
plexes Opti-MEM I medium (Gibco), siPORT™ NeoFX™ transfection
reagent (Ambion), reporter gene plasmid DNA (45 ng/well) and pre-
cursor miRNA (pre-miR) molecules of candidate miRNAs (pre-miR-
34c-5p or pre-miR-212-3p) in a ﬁnal concentration of 2.5 and
10 nM or 1.0 and 2.5 nM, respectively, were combined according to
the manufacturer's recommendation. Endogenous cellular miRNA ex-
pression was normalized by co-transfecting each reporter plasmid
with precursor miRNA negative control molecules (pre-miR-NC) at
the same concentrations as described above. Potential indirect
miRNA-mediated effects on promoter activity were assessed by co-
transfecting empty pmirGLO or psicheck2S vectors with the same
concentrations of pre-miRs of candidate miRNAs or pre-miR-NC. All
pre-miR molecules were purchased from Ambion. Four hours after
transfection, mediumwas replaced by fresh growth medium. The ac-
tivities of both ﬁreﬂy and Renilla luciferases were determined 48 h
after transfection using the Dual-Luciferase® Reporter Assay System
(Promega) according to the manufacturer's recommendation and
Veritas Software coupled to the Veritas microplate luminometer
(Tuner Biosystems, Sunnyvale, CA, USA). The Fireﬂy luciferase
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activities to control for transfection efﬁciency, and the Renilla lucifer-
ase activities of psicheck2S plasmids were normalized to Fireﬂy lucif-
erase activities, respectively. Seven biological replicates were
included in each experiment, and each experiment was repeated
with two different concentrations of pre-miR-molecules. Reporter
gene activities in cells co-transfected with plasmids and pre-miR
are shown relative to those obtained from cells co-transfected with
the same plasmid and pre-miR-NC.
Isolation and culture of primary rat cortical neonatal neurons
Mixed cortical cultures containing both neurons and astrocyteswere
prepared as described previously (Brewer, 1995) andmodiﬁed recently
(Zhao et al., 2006). In brief, medium I (DMEM containing 10% FCS, 100
U/ml penicillin and 100 μg/ml streptomycin) and medium II
(neurobasal medium containing 2% B27 supplement, 0.5 mM L-gluta-
mine, 100 U/ml penicillin, and 100 μg/ml streptomycin) (Gibco) were
pre-warmed. Immediately after sacriﬁce the cerebral cortices of 0 to
1 day neonatal Wistar rats were dissected and dispersed using 0.25%
trypsin (Gibco), followed by gentle trituration. After washing twice
with neurobasal medium and once with medium I at 1000 rpm for
4 min, cells were counted and seeded in poly-L-lysine (0.1 mg/ml,
Sigma-Aldrich) pre-coated 4-well culture plates in medium I. After 3 h
incubation, culture medium I was replaced with culture medium II,
and the cells were maintained in a humidiﬁed atmosphere of 5% CO2
at 37 °C.
The time-dependent expression of Sox11 mRNA, miR-212-3p and
miR-132-3p was monitored at 13 different time points (0, 12, 24, 36,
48, 60, 72, 84, 96, 108, 120, 132 and 144 hours) with total RNA isolation
using a mirVana miRNA Isolation Kit (Ambion).
Electroporation of primary rat cortical neonatal neuronswithmiRNA inhib-
itors (anti-miRs)
Cortical cells were isolated as described above. Five aliquots of 4.8 x
106 cells eachwere centrifuged for 5min at 80 g. Cell pelletswere resus-
pended in 100 μl Nucleofector® solution (Amaxa® Rat Neuron
Nucleofector® Kit, Lonza, Cologne, Germany) and spiked with the
miRNA inhibitor molecules anti-miR-212-3p, anti-miR-132-3p or anti-
miR-NC at a concentration of 150 nM, or with both anti-miR-212-3p
(150 nM) and anti-miR-132-3p (150 nM) or with anti-miR-NC (300
nM) (Ambion), respectively. After 10 minutes of incubation, electropo-
ration was conducted using an Amaxa® Nucleofector® I (Lonza) and
the appropriate electroporation program (G13) according to the
manufacturer's recommendation. Cell suspension from each electropo-
rationwas diluted and aliquoted in two poly-L-lysine- (0.1 mg/ml) pre-
coated 4-well culture plates, containing 500 μl Medium I perwell. Medi-
um I was replaced with medium II after 3 h incubation and cells were
maintained as described above. At eight different time points (0, 12,
24, 48, 60, 72, 96 and 144 hours) total RNA was isolated for determina-
tion of Sox11 mRNA expression.
Quantiﬁcation of time-dependent mRNA and miRNA expression in rat cor-
tical neurons
Total RNA isolated from naïve or transfected primary rat cortical
neonatal neurons was subjected to DNAse treatment (TURBO DNA-
free™ Kit, Ambion). Next, 100 ng of total RNA per sample was reverse
transcribed (Transcriptor High Fidelity cDNA Synthesis Kit, Roche,
Mannheim, Germany) and cDNA quantiﬁcation was performed using
TaqMan® assays (rat Sox11: assay ID: Rn00584322_s1, rat ACTB (β-
Actin): Cat. No.: 4352340E) and TaqMan® Universal Master Mix II, no
UNG. In parallel, total RNA (50 ng per sample) was reverse transcribed
using a pool of miR-212-3p, miR-132-3p and U6snRNA speciﬁc RT
primers and the TaqMan® MicroRNA Reverse Transcription Kit(Applied Biosystems). After an additional pre-ampliﬁcation step similar
to that described above, miRNA expression was determined with indi-
vidual TaqMan® MicroRNA assays (assay ID: 000515, 000457 and
001973, respectively) and TaqMan® Universal Master Mix II, no UNG
(all assays andmastermixeswere purchased fromApplied Biosystems).
All quantitative real-time PCR reactions were run on an ABI prism
7900HT (Applied Biosystems) in duplicate. qRTPCR data were
expressed as 2-ΔCt, using rat ACTB or U6snRNA as endogenous controls.
Staining and immunoﬂuorescence microscopy of transfected rat neurons
Primary neuronal cells were transfected by electroporation with
pmaxGFP™ vector (Lonza) and additionally with identical anti-miRs
or anti-miR combinations (anti-miR-212-3p, anti-miR-132-3p, anti-
miR-NC) in identical concentrations as described above. Cells were cul-
tured on poly-L-lysine (0.1 mg/ml) pre-coated cover slips placed in 4-
well culture plates. Cells were ﬁxed after four different time points
(24, 48, 72, and 96 hours after plating) with 4% paraformaldehyde in
PBS for 1 h at 4 °C, washed, and permeabilized with 0.3% TritonX-100
in PBS for 5 min. After blocking with 1% BSA, primary neuronal cells
were incubated with the primary rabbit anti-rat Sox11 antibody (H-
290) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) (1:300) at 4 °C
overnight. After washing with PBST (PBS containing 0.1% Triton X-
100), the cells were incubated with the corresponding secondary anti-
body (Alexa Fluor®546-conjugated goat anti-rabbit antibody; Molecu-
lar Probes by Life Technologies, Leiden, The Netherlands) in 0.5% BSA
at 37 °C for 1 h in the dark. After washing twice with PBST and once
with PBS and subsequent drying at room temperature, the cells were
mounted in ProLong® Gold Antifade Reagent (Molecular Probes). For
qualitative analysis, stained primary neuronal cells were analyzed
with a Leica DMR ﬂuorescence microscope (Leica, Wetzlar, Germany).
In silico analysis of putative transcription factor binding sites
The region 3000 bp 5′-upstream of the ATG start of rat and
human SOX11 (Ensembl gene browser ID: ENSRNOG00000030034,
ENSG00000176887) as well as 3000 bp 5′-upstream of miR-212/
132 (ENSRNOG00000035476, ENSG00000267195) were evaluated
for putative transcription factor binding sites using the Transfac®
database (release 2013.2) (Matys et al., 2006). For each transcription
factor binding site search the software tool was preset to
“vertebrate_non_redundant_minFP” and “proﬁle-speciﬁc-cutoff”.
Statistical analysis
Comparisons of miRNA expression between the human brain tissue
types were performed as described above. GraphPad Prism version 5.0
for Windows (GraphPad Software, San Diego California, USA) was
used to perform a Mann–Whitney U test for differences in normalized
reporter gene activities between HepG2 cells co-transfected with re-
spective candidate pre-miRs and either empty vector or one of the var-
ious cloned 3′-UTR target sequence reporter gene plasmids. Linear
regressionwas performed to test for positive or negative correlation be-
tween mRNA and miRNA expression in primary rat neurons over the
monitored time period.
Results
miRNA screen in human brain tissue
Out of 754 miRNAs on a TaqMan® low density array, 215 miRNAs
were detected in all 16 (8 hippocampal focal, 8 temporal neocortical
non-focal) human brain tissue samples. miRNAs with the highest medi-
an overall expression levels (top 3% of all detected miRNAs) were hsa-
miR-125b-5p, hsa-miR-218-5p, hsa-miR-150-5p, hsa-miR-30c-5p, hsa-
miR-24-3p, and hsa-miR-99b-5p. These miRNAs were not differentially
Table 2
Vector systems and inserted target gene 3′-UTR sequences used in reporter gene assays for target gene evaluation of hsa-miR-212-3p and hsa-miR-34c-5p.
Target
gene
mRNA Acc.
number
Position of
3′-UTR
sequence of
insert
miRNA
predicted to
bind to 3′-UTR
sequence
Location of miRNA
binding
site in 3′-UTR
sequence
Name and sequence
of forward primer
Name and sequence
of reverse primer
Name of
vector
system
Name of
vector
construct
ABCG2 NM_004827.2 484-663 hsa-miR-212-3p 588-607† FW-ABCG2-V1:
5‘-CTCGTTT‘AAACAAAAA
AAGCCACCGTGATAGAAA
RV-ABCG2-V1:
5′-GAGT⁎CTAGAGTTCCA
GAAATGGTGCAAGAAT
psicheck2S ABCG2-V1
ABCG2 NM_004827.2 1328-1462 hsa-miR-212-3p 1411-1417‡ FW-ABCG2-V2:
5‘-CTCGTTT‘AAACCTCTTT
GCTCAGCTTCCCTTAAT
RV-ABCG2-V2:
5′-GAGT⁎CTAGATTAGTG
GAAAAGTGGTGAAATCG
psicheck2S ABCG2-V2
ADCY1 NM_021116.2 1-612 hsa-miR-212-3p 268-290† FW-ADCY1-V1
5‘-CTCGTTT‘AAACTGGAG
CCCACGTGGGCCTCTGGGGTGC
ACA
RV-ADCY1-V1
5′-GAGT⁎CTAGATTCTCC
CCAGACGGTCCAGTTCA
AGAGTGGAC
psicheck2S ADCY-V1
ADCY1 NM_021116.2 2853-3622 hsa-miR-212-3p 3246-3252‡ FW-ADCY1-V2
5‘-CTCGTTT‘AAACGATTC
GAAGTGTCACAGAGATGGTGCC
GTC
RV-ADCY1-V2
5′-GAGT⁎CTAGAAGCATG
GCCAAGCAAGGGCTGAGGTG
GGTGTG
psicheck2S ADCY-V2
SOX11 NM_003108.3 51-523 hsa-miR-212-3p 509-515‡ FW-SOX11-V1:
5‘-CTCGTTT‘AAACTTGG
GAGGAAGTTGTAGTGG
RV-SOX11-V1:
5′-GAGT⁎CTAGACCCTAG
AGTAACAGTTGTGC
psicheck2S SOX11-V1
SOX11 NM_003108.3 6500-7199 hsa-miR-212-3p 6620-6641‡,§,
6954-6973†
FW-SOX11-V2:
5‘-CTCGTTT‘AAACCTCCC
TTGAATCACATAGGG
RV-SOX11-V2:
5′-GAGT⁎CTAGAGAAGCT
GGTTAGATCGAAGC
psicheck2S SOX11-V2
BSN NM_003458.3 362-616 hsa-miR-212-3p 485-505† FW-BSN V1:
5‘-CTCGTTT‘AAACTACTT
CCCACAGCCGCCTTTT
RV-BSN V1:
5′-GAGT⁎CTAGAGGCCA
CATGGAGGTCTGCT
psicheck2S BSN-V1
BSN NM_003458.3 1240-1537 hsa-miR-212-3p 1382-1392‡ FW-BSN V2:
5‘-CTCGTTT‘AAACGGGGA
ATGTGGCACTGTCT
RV-BSN V2
5′-GAGT⁎CTAGA TGCCA
CAGACTGAGAATTTCAC
psicheck2S BSN-V2
MECP2 NM_004992.3 6294-7203 hsa-miR-212-3p 6591-6610†,
6887-6893‡,&
FW-MECP2:
5‘-CTCGTTT‘AAACTCCAG
AAACTTGTTCTTCCAAAGCAG
RV-MECP2:
5′-GAGT⁎CTAGATACTTTA
AACATAGTTACAATACAGA
psicheck2S MECP2
GABRA3 NM_000808.3 1-1066 hsa-miR-34c-5p 221-227‡,§,
256-282†,
722-728‡,§
FW-GABRA3:
5‘-CTCGTTT‘AAACATAGT
GGTGGCAGTGCAGCAAC
CAGAGCACTGT
RV-GABRA3:
5′-GAGC#TCGAGTGCCTG
GGCCAGGGTGTGGAATGTGG
AGTGTA
pmiRGLO GABRA3
GABBR2 NM_005458.7 259-425 hsa-miR-34c-5p 393-418† FW-GABBR2 V1:
5‘-CTCGTTT‘AAACAAACA
AGGAGGCGCTGGGATAT
RV-GABBR2 V1:
5′-GAGT⁎CTAGATGTGCA
GAGGCAGTTTCTTCAGA
pmiRGLO GABBR2-V1
GABBR2 NM_005458.7 2282-2433 hsa-miR-34c-5p 2384-2389‡ FW-GABBR2 V2:
5‘-CTCGTTT‘AAACTCTTTT
ATATGCAGCAAACACACC
RV-GABBR2 V2:
5′-GAGT⁎CTAGACATGCA
GTAGGGGTACGAGAAATT
pmiRGLO GABBR2-V2
GRM7 NM_181874.2 1-1196 hsa-miR-34c-5p 281-287‡,§,
266-287†
FW-GRM7:
5‘-CTCGTTT‘AAACCTTTT
GACTGCTTTCCCAAAGGCCCTG
CTGCA
RV-GRM7:
5′-GAGT⁎CTAGAAAAAAG
TTAACCAAAGTATTTTATTGAT
ACAT
pmiRGLO GRM7
MBD6 NM_052897 365-869 hsa-miR-34c-5p 663-673‡,§,
756-789†
FW-MBD6: 5‘-CTCGTTT‘AAAC
CCCTTCT
TAAAGCCAACAGGC
RV-MBD6:
5′-GAGT⁎CTAGAATAGAA
AAGCAGTGGAGGCCC
pmiRGLO MBD6
‘Pme I restriction site.
Predicted by target gene prediction database †RNAHybrid, ‡Targetscan 5.2, §miRanda, &PicTar.
⁎ Xba I restriction site.
# Xho I restriction site.
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the 215miRNAs revealed similarity in the expression proﬁles ofmiRNAs
in samples from hippocampal focal compared to temporal neocortical
non-focal brain tissue samples (Fig. 1A). A comparison ofmiRNA expres-
sion levels in focal and non-focal tissue identiﬁed 16 miRNAs showing
an unadjusted p-value ≤0.05: hsa-miR-212-3p, hsa-miR-221-3p, hsa-
miR-99b-3p, hsa-miR-335-5p, hsa-miR-495, hsa-miR-103a-3p, hsa-
miR-129-1-3p, hsa-miR-504-5p, hsa-miR-129-2-3p, hsa-let-7a-5p,
hsa-let-7e-5p, hsa-miR-592 were down-regulated and hsa-miR-34c-
5p, hsa-miR-184, hsa-miR-27a-3p andhsa-miR-494-3pwere upregulat-
ed in focal compared to non-focal tissue. Of these 16 miRNAs, three
showed a p-value ≤0.02 and in parallel a log2-transformed fold change
of ≥2.0 (Fig. 1B). hsa-miR-34c-5p was upregulated 5.7 fold in hippo-
campal focal tissues compared to non-focal temporal neocortical tissues
(p = 0.014, q-value = 0.32), whereas hsa-miR-212-3p and hsa-miR-
221-3p were down-regulated 76.9% (p = 0.0014, q-value = 0.28) and
74.9% (p = 0.0028, q-value = 0.28), respectively. These data wereeven more pronounced, when miRNA expression of hippocampal focal
and temporal neocortical non-focal tissue of additional ﬁve therapy-
resistant MTLE patients were regarded (see supplementary Fig. 1S).
Since demographic and histhopathological information was not avail-
able for those patients, these data were not included in the initial
comparison.
Nevertheless, since the initial array data revealed relatively high FDR
adjusted p-values (q-values), the differential expression between hip-
pocampal focal and temporal neocortical brain tissue for hsa-miR-34c-
5p, hsa-miR-212-3p and hsa-miR-221-3p was re-evaluated with indi-
vidual TaqMan assays. The differential expression of hsa-miR-34c-5p
and hsa-miR-212-3p was conﬁrmed (mean change: 8.3-fold increase
(p = 0.008) and 33% decrease (p = 0.04), respectively). In contrast,
no signiﬁcant difference in expression of hsa-miR-221-3p between hip-
pocampal focal and temporal neocortical non-focal brain tissue was de-
tected. Based on these ﬁndings, hsa-miR-34c-5p and hsa-miR-212-3p
were chosen for further functional studies.
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from autopsies no signiﬁcant difference in expression of hsa-miR-212-
3p between hippocampal and frontal cortical brain tissue was observed
(Fig. 5B).
In silico search for target genes of candidate miRNAs
Putative target genes of hsa-miR-34c-5p and hsa-miR-212-3p were
identiﬁed using two approaches. The aim of the ﬁrst (hypothesis-guid-
ed) approachwas to take into consideration common hypotheses about
the pathophysiology of epilepsy syndromes, especially those showing
an intractable phenotype such as MTLE. By using four different predic-
tion databases (TargetScan 5.2, RNAHybrid, PicTar and miRanda), com-
mon ABC transporters (ABCB1, ABCC1, ABCC2, ABCC4 and ABCG2) often
implicated in pharmacoresistance were tested for putative interaction
with hsa-miR-34c-5p and hsa-miR-212-3p. In addition, two gene lists
containing 564 (hsa-miR-34c-5p) and 341 (hsa-miR-212-3p) target
genes were generated using the GOmir software application
(Roubelakis et al., 2009) and the same databases. Given the critical
role of gamma-aminobutyric acid (GABA) and glutamate as determi-
nants of neuronal network excitability, these lists were selectively
searched for genes involved in GABAergic and glutamatergic neuronal
signal transmission. The efﬂux transporter ABCG2 was identiﬁed as a
putative target of hsa-miR-212-3p and GABA B receptor 2 (GABBR2),
glutamate receptor, metabotropic 7 (GRM7) and GABA A receptor,
alpha 3 (GABRA3) were predicted targets of hsa-miR-34c-5p (Fig. 1C).
The second approach was designed to be hypothesis-generating.
GOmir (Roubelakis et al., 2009) identiﬁed the following number of pu-
tative targets of the six highest expressed miRNAs (top 3% of miRNAs
detected in all 16 investigated human brain samples): hsa-miR-218-
5p (n = 784 predicted target genes), hsa-miR-30c-5p (n = 1250),
hsa-miR-150-5p (n = 214), hsa-miR-125b-5p (n = 670), hsa-miR-
24-3p (n=546), hsa-miR-99b-5p (n=41). These six lists were ﬁltered
for genes that were targeted by at least three of the six most highly
expressed miRNAs and additionally by one of the selected differentially
expressed candidate miRNAs. There is evidence from literature, that
some of these miRNAs, namely hsa-miR-218-5p and hsa-miR-125b-
5p, are typically brain-enriched miRNAs (Sempere et al., 2004) and
McKiernan et al. also found hsa-miR-218-5p, hsa-miR-30c-5p, hsa-
miR-125b-5p and hsa-miR-24-3p amongst the top 40 expressed
miRNAs in healthy hippocampus (McKiernan et al., 2012a), supporting
the validity of our array data. The intention underlying this ﬁltering ap-
proach was to use the most highly expressed miRNAs to uncover genes
that are more likely to be critical for normal brain function and to result
in crucial functional impairments as a result of altered miRNA expres-
sion. The conduction of this approach revealed adenylate cyclase 1
(brain) (ADCY1), bassoon presynaptic cytomatrix protein (BSN), meth-
yl CpG binding protein 2 (MECP2) and SRY (sex determining region Y)-
box 11 (SOX11) to be targets of hsa-miR-212-3p, whereas ADCY1 was
additionally predicted to be targeted by hsa-miR-218-5p, hsa-miR-
125b-5p and hsa-miR-99b-5p; BSN by hsa-miR-218-5p, hsa-miR-30c-
5p, hsa-miR-150-5p, hsa-miR-125b-5p and hsa-miR-24-3p; MECP2 by
hsa-miR-218-5p, hsa-miR-30c-5p and hsa-miR-24-3p and SOX11 by
hsa-miR-218-5p, hsa-miR-30c-5p, hsa-miR-125b-5p and hsa-miR-24-
3p. Methyl-CpG binding domain protein 6 (MBD6) was predicted as a
putative target of hsa-miR-34c-5p, and the 3′-UTR of MBD6 harbored
additional putative binding sites for hsa-miR-30c-5p, hsa-miR-150-5p,
miR-24-3p and hsa-miR-99b-5p (Fig. 1C).
Reporter gene assay after transient co-transfection of HepG2 cells with 3′-
UTR target sequence plasmids and precursor-miRNAs
RNA interference between predicted 3′-UTR sequences of putative
target genemRNAs and selected respective candidatemiRNAswas eval-
uated using reporter gene assays. The 3′-UTR sequence of GABRA3
mRNA was identiﬁed as a target of hsa-miR-34c-5p based on areduction in normalized reporter gene activities of 39-46% relative to
empty pmiRGLO vector following co-transfection with 10 nM (p =
0.002) and 2.5 nM ( p= 0.002) pre-miR-34c-5p. The 3′-UTR sequences
of GRM7 and of GABBR2 containing the predicted distal hsa-miR-34c-5p
binding site were targeted after co-transfection of 10 nM pre-miR-34c-
5p; a mean reduction in reporter gene activities of 37.5% (p = 0.001)
and 32.4% (p = 0.002), respectively, was observed. The putative proxi-
mal binding site in the GABBR2-3′-UTR and the binding site in the 3′-
UTR sequence of MBD6 were not targeted by hsa-miR-34c-5p (Fig. 2A
and B).
Reporter gene activities ofMECP2 and SOX11-V2 (containing 3′-UTR
sequence with two more distal predicted hsa-212-3p binding sites)
plasmids were signiﬁcantly reduced by 1.0 nM (MECP2: 32%, p =
0.03; SOX11-V2: 30%, p = 0.03) and 2.5 nM (MECP2: 51%, p = 0.003;
SOX11-V2: 64%, p = 0.0007) pre-miR-212-3p. Only the higher concen-
tration of pre-miR-212-3p reduced luciferase activity of the ABCG2-V2
or ADCY1-V2plasmids (21%, p=0.04 and36%, p=0.009), respectively.
Plasmids containing 3′-UTR sequences of BSN (BSN-V1 carrying a pre-
dicted proximal and BSN-V2 carrying a predicted distal binding site),
and 3′-UTR sequences of ADCY1, SOX11 and ABCG2 with predicted
proximal hsa-miR-212-3p binding sites showed no signiﬁcant down
regulation in reporter gene assays (Fig. 2 C and D).
Identiﬁcation of binding sites of tandemmiRNAs hsa-miR-212-3p and hsa-
miR-132-3p in SOX11-3′-UTR
Reporter gene assays found the strongest interference between
miRNA and its mRNA target sequence for hsa-miR-212-3p and SOX11.
However, SOX11 was not previously veriﬁed as a target of hsa-miR-
212-3p. Since it is known that hsa-miR-212-3p and hsa-miR-132-3p
are not only processed from the same primary transcript, but also
share a similar mature sequence and an identical seed region (tandem
miRNAs) (Wanet et al., 2012), we hypothesized that SOX11 is not
only targeted by hsa-miR-212-3p, but also by hsa-132-3p. The array
analysis indicated a non-signiﬁcant mean difference in hsa-miR-132-
3p between hippocampal focal versus temporal neocortical non-focal
human brain tissue (35% decrease, p = 0.32). Reporter gene assays
were used to investigate further the miRNA/mRNA interaction and the
location of binding sites of hsa-miR-212-3p and hsa-miR-132-3p in
the SOX11-3′-UTR. The SOX11-V2 plasmid contained two different pu-
tative miRNA binding sites and was mutated at either the proximal or
distal site or at both hsa-miR-212-3p binding sites (Fig. 3). Empty
psicheck2S vector or wildtype or mutated SOX11-V2 reporter plasmids
were co-transfected with pre-miR-212-3p or pre-miR-132-3p or pre-
miR negative control in HepG2 cells at a concentration of 2.5 nM each.
Treatment with pre-miR-212-3p resulted in a decrease in wild type
SOX11-V2 reporter activity (55.6% decrease, p = 0.002); the activity
of the single and doublemutant plasmidswas reduced to a lesser degree
(SOX11-V2-mut-TS: 28.0% decrease, p = 0.026; SOX11-V2-mut-RHy:
43.9% decrease, p = 0.004; and SOX11-V2-mut-dko: 22% decrease,
p = 0.097) (Fig. 3A). Similar results were found for treatment with
pre-miR-132-3p; reporter gene activities were decreased 34.9% (p =
0.026), 22.2% (p = 0.165), 19.6 % (p = 0.165) and 12.6% (p = 0.383)
for the wild type, SOX11-V2-mut-TS, SOX-11-V2-mut-RHy and
SOX11-V2-mut-dko plasmids, respectively. These results identiﬁed
two nucleotide sites (position 6620–6641 and 6954–6973 of SOX11-
3′-UTR) that annealed to hsa-miR-212-3p and hsa-miR-132-3p, with
the latter having a smaller inﬂuence on SOX11 expression compared
to hsa-miR-212-3p. Moreover, since the mutation of the putative prox-
imal binding site (SOX11-V2-mut-TS) led to less pronounced down-
regulation of the reporter activity compared to mutation of the distal
binding site (SOX11-V2-mut-RHy), hsa-miR-212-3p seems to have a
stronger negative effect on SOX11 expression via the proximal than
thedistal binding site. Additionally, these results suggest that bothbind-
ing siteswork additively in controlling SOX11 expression via interaction
with hsa-miR-212-3p as well as hsa-miR-132-3p.
Fig. 2. Evaluation of 3′-UTR functional activity and regulation bymiRNAs. Reporter gene activities weremeasured in HepG2 cells co-transfected with 3′-UTR target sequence plasmids and
two concentrations of pre-miRs for candidate miRNAs hsa-miR-34c-5p (A and B) and hsa-miR-212-3p (C and D) predicted to interfere with the 3′-UTR sequence of target gene mRNAs
(n = 7). To exclude potential effects of endogenous expressed miRNAs, activities have been normalized to activities obtained from cells co-transfected with respective 3′-UTR target
sequence plasmids and pre-miR-negative control. V1-labeledplasmids contain respective 3′-UTR sequences containing predictedproximally locatedmiRNA binding site(s) andV2-labeled
plasmids contain respective 3′-UTR sequences containing predicted distally located miRNA binding site(s) (see also Table 2). Values are means ± standard error of the mean (SEM).
Interference of candidatemiRNAswith targetmRNAwere testedwith aMann–WhitneyU test, whereas in each experiment normalized activities of cells co-transfectedwith empty vector
plasmids and respective identical concentrations of pre-miR molecules were used as calibrator. *, **, *** indicate p-values ≤ 0.05, 0.01, and 0.001, respectively.
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and anti-miR-transfected neonatal rat neurons
Adult neurogenesis is an essential and widely conserved process in
themajority of mammals. During neurogenesis, the neuronal transcrip-
tion factor SOX11 is involved in initiation of neuronal differentiation.
Protein sequences of human (acc. no.: NP_003099.1) and rat (acc. no.:
NP_445801.1) SOX11 are highly homologous. Comparison of both
sequences using the NCBI HomoloGene tool (http://www.ncbi.nlm.
nih.gov/homologene?LinkName=protein_homologene&from_uid=
4507161) revealed several human-rat sequence alignments with the
highest percent identity of 96% found for the sequence alignment
from position 1–139. The percentage of human sequence covered by
alignment to the rat sequence was 82%. Thus, we hypothesized that
rat Sox11 was similarly regulated by miR-212-3p/132-3p as its human
homolog. An in silico search using RNAhybrid software identiﬁed a nu-
cleotide sequence (position 354–374 of rat Sox11-3′-UTR, acc. no.:
NM_053349.1) predicted to be targeted through hsa-miR-212-3p and
hsa-miR-132-3p.
miR-212-3p/132-3p-mediated control of SOX11 expressionwas fur-
ther investigated by examining the time-dependent expression of both
miRNAs and rat Sox11mRNA in differentiating neurons cultured in nor-
mal growth medium after isolation from neonatal rat brains. A signiﬁ-
cant inverse correlation was observed between Sox11 mRNA and both
miR-212-3p (R2 = 0.33, p = 0.04) and miR-132-3p (R2 = 0.34, p =
0.04) over 144 hours in culture. However, closer inspection indicatedthat Sox11 mRNA and both miR-212-3p (R2 = 0.96, p = 0.0004) and
miR-132-3p (R2 = 0.61, p = 0.005) were concurrently up-regulated
over the initial 48 hr culture period. In contrast, from 60 to 144 hours
Sox11 mRNA tended to show an inverse relationship with miR-212-3p
(R2 = 0.45, p = 0.07) and miR-132-3p (R2 = 0.28, p = 0.17) expres-
sion, and Sox11 mRNA was suppressed compared to early time points
(Fig. 4A and B). This observation is consistent with an initial common
transcriptional mechanism controlling expression of Sox11 and the pri-
mary transcript containing the tandem miRNAs miR-212-3p and miR-
132-3p,which subsequently act as negative post-transcriptional regula-
tors of SOX11.Quantiﬁcation of time-dependent Sox11mRNA expression and immunoﬂu-
orescence microscopy of Sox11 protein in neonatal rat neurons transfected
with anti-miRs
Time-dependent Sox11 mRNA expression was measured after trans-
fection of anti-miR molecules antagonizing endogenous expression of
miR-212-3p or miR-132-3p in freshly isolated neurons of neonatal rats.
Antagonism of only one or both miRNAs resulted in a time-dependent
down-regulation of Sox11 mRNA, which was more pronounced with
anti-miR-132-3p than with anti-miR-212-3p. Interestingly, in neurons
transfected with both anti-miR-212-3p and anti-miR-132-3p, Sox11
mRNA was not down-regulated and showed a tendency to be up-
regulated over a 144 hr observation period (Fig. 5).
Fig. 3. Functional miRNA binding sites on SOX11-3′-UTR. Normalized reporter gene activities in HepG2 cells co-transfected with wild type or mutated SOX11-V2-3′-UTR target sequence
plasmids and 2.5 nM of pre-miR-212-3p (A) or pre-miR-132-3p (B) (n = 7). All activities (mean ± SEM) have been normalized to activities obtained from cells co-transfected with re-
spective 3′-UTR target sequence plasmids and pre-miR-negative control. * and ** indicate p-values≤ 0.05 and ≤ 0.01, respectively. Bold characters indicate sequence complementary to
miRNA seed sequence, red characters indicate mutated nucleotides. SOX11-V2-mut-TS contains mutated miRNA binding site predicted by Targetscan 5.2, SOX11-V2-mut-RHy contains
mutated miRNA binding site predicted by RNAHybrid, and SOX11-V2-mut-dko contains SOX11-V2-3′-UTR sequence with both predicted binding sites mutated.
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after transfection with anti-miR molecules revealed lower Sox11 pro-
tein in cells transfectedwith one anti-miR compared to cells transfected
with anti-miR-212-3p and anti-miR-132-3p, with the lowest signal
intensity seen in anti-miR-132-3p transfected neurons. Cells double
transfected with anti-miR-212-3p and anti-miR-132-3p not only
showed the strongest Sox11 protein signal, but also a less differentiated
morphology with a reduced dendrite-like structure (Fig. 5).
Putative transcription factor binding sites in promoter region of rat and
human SOX11 and primary transcript of miR-212-3p/132-3p
Based on the observed concurrent initial transcription of Sox11 and
miR-212-3p as well as miR-132-3p in primary cortical rat neurons
(Fig. 4), the question arose whether SOX11 is a transcription factor for
its own regulator miR-212-3p/132-3p or rather SOX11 and the primary
transcript of miR-212-3p/132-3p share a common set of yet unknown
transcription factors.
Assuming a similar interplay between SOX11 and miR-212-3p/132-
3p in man and rat, the 5′-UTR of rat and human SOX11 and the primary
transcript for miR-212-3p/132-3p were scanned from position−1 to
−3000 for putative transcription factor binding sites using the
Transfac® database. Response elements for SP1 (primary accession ID:
M00933), DR3 (primary accession ID: M00966) and EBOX (primary
accession ID: M01034) were predicted for all four 5′-UTR sequences.
All binding sites were classiﬁed as family matrix transcription factor
binding sites, meaning that a group of related transcription factors
may bind at those sites. Additionally, in all four sequences a factor
speciﬁc binding site for PAX3 (primary accession ID: M00327) was
found. Since no SOX11 binding site was identiﬁed in the 5′-UTR region
of the primary transcript miR-212-3p/132-3p, the observed initialconcurrent regulation of both transcripts may be mediated by shared
transcription factors rather than via direct induction of miR-212/132
through SOX11.
Discussion
Neurogenesis persists in the subventricular zone (SVZ) of the tem-
poral ventricles and the subgranular zone (SGZ) of the hippocampus
throughout adulthood. In the SGZ, learning and physical exercise can
stimulate neurogenesis, whereas neurotransmitters, growth factors,
cytokines, and hormones stage-speciﬁcally inﬂuence proliferation of
neural stem cell derived progenitor cells and their differentiation into
mature neurons (Masiulis et al., 2011;Ming and Song, 2011). Moreover,
in certain epilepsy types, e.g. MTLE aswell as in animal epilepsymodels,
acute seizures can promote hippocampal neurogenesis (Parent et al.,
1997, 2006; Thom, 2004). It is speculated that seizure-induced newborn
granule cells exhibit altered molecular and physiological properties
likely associated with altered excitability. In the chronic stage of epilep-
sy, however, in the hippocampus the number of neuronal stem cells
(NSCs) seems not to change signiﬁcantly. However, the process of prop-
er differentiation of NSC progenies into mature neurons appears to be
impaired (Crespel et al., 2005; Hattiangady and Shetty, 2008; Kralic
et al., 2005; Kuruba et al., 2009). miRNAs are important regulators of
cellular processes and are also involved in the ﬁne-tuning of the stage-
speciﬁc control of neurogenesis (Sun et al., 2012). Comparing two
brain tissue types, one without the potential of adult neurogenesis
(temporal neocortex) and one with signs of abnormalities in
neurogenesis, the current study was designed to further explore the
roles of miRNAs in aberrant epilepsy-related hippocampal cellular
remodeling. A small set of 16 miRNAs were found to be differentially
expressed between hippocampal focal and temporal neocortical non-
Fig. 4. Time-dependent changes in the expression of Sox11,miR-132-3p andmiR-212-3p in differentiating rat neurons. (A) Time-dependent Sox11mRNA andmiR-132-3p andmiR-212-3p
expression in differentiating neonatal rat neurons. B) Linear regression of Sox11 mRNA and miR-132-3p and miR-212-3p expression over 144 hours (left panel) or from 0–60 hr and
60–144 hr (right panel).
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184 was elevated 8.0-fold in focal hippocampal tissue compared to
non-focal neocortical tissue. hsa-miRNA-184 was previously shown to
be up-regulated in mouse hippocampus eight hours after seizure pre-
conditioning with an intraperitoneal injection of kainate (McKiernan
et al., 2012b) and it was suggested thatmiR-184 protects against neuro-
nal cell death (McKiernan et al., 2012b) and promotes proliferation of
adult hippocampal neural progenitor cells, inhibiting their differentia-
tion (Liu et al., 2010; Sun et al., 2012). Hippocampal miR-27a was also
reported to be up-regulated (Hu et al., 2012) and let-7e was increased
24 hours and decreased 50 days after lithium-pilocarpine-induced sta-
tus epilepticus (SE) compared to control rats (Song et al., 2011). hsa-
miR-212-3p was reported to be differentially regulated in a time-
dependent manner after electrically stimulated SE in rat hippocampus
(Bot et al., 2013) and hsa-miR-221 was down-regulated in human hip-
pocampi of TLE patients exhibiting hippocampal sclerosis (HS) (Kan
et al., 2012). In the current study, hsa-miR-34c-5p was increased more
than 5-fold in focal hippocampal tissue compared to temporal neocorti-
cal non-focal tissue. Although hsa-miR-34c-5p has not yet been associ-
ated with any epilepsy model, it shares an identical seed region with
miR-34a, a miRNA that was up-regulated in the hippocampus
24 hours after lithium-pilocarpine-induced SE in rat (Hu et al., 2011)
and after intra-amygdala-injection of kainic acid in mice (Sano et al.,
2012). These data and our results imply that a certain set of miRNAs
show an epilepsy-associated altered expression proﬁle. However, the
expression of some miRNAs varies as a function of the stage of disease
and probably also with the epilepsy model.
Filtering for target genes of hsa-miR-34c-5p and hsa-miR-212-3p re-
vealed a set of nine genes putatively involved in GABAergic and gluta-
matergic signal transmission (GABRA3, GABBR2, GRM7, BSN),
neuronal cAMP formation (ADCY1), neuronal gene regulation (SOX11,
MECP2, MBD6) and drug efﬂux (ABCG2). All except for BSN and
MBD6 interacted with the miRNAs in vitro. A negative regulation ofGRM73′-UTR and the distal GABBR23′-UTRbyhsa-miR-34c-5pwasde-
tected (Fig. 2B). In addition to being an important excitatory neuro-
transmitter, glutamate is also necessary for the normal survival and
integration of newborn granule neurons in the dentate gyrus, while
also inhibiting proliferation of neuronal stem cells (Berg et al., 2013;
Ming and Song, 2011; Tashiro et al., 2006). Glutamate mediates inhibi-
tory effects on presynaptic calcium channels and on adenylate cyclase
via the metabotropic glutamate receptor 7 (GRM7), a presynaptic
expressed G-protein coupled receptor, thus controlling intracellular
cAMP formation and glutamate release from the presynaptic axonal ter-
minal (Benarroch, 2008). GRM7 was shown to be inversely expressed
with miR-34a-5p in rat hippocampi after lithium and valproate treat-
ment, suggesting an anticonvulsive mechanism of action of both drugs
via miRNA-mediated gene regulation (Zhou et al., 2009). The current
ﬁndings support the assumption of an overlap of target genes of miR-
34a-5p and miR-34c-5p. GABAB receptor, also a G-protein coupled re-
ceptor, comprises subunits 1 and 2, and both subunits have to correctly
dimerize to properly mediate inhibitory effects of GABA on voltage de-
pendent calcium channels and activating effects on potassium channels,
thus playing an important role in controlling neuronal excitability and
hippocampal long term potentiation (Benarroch, 2012). Moreover,
pharmacological inhibition of GABAB receptors led to increased prolifer-
ation of neuronal stem cells (Giachino et al., 2014).
GABRA3 3′-UTR showed the strongest negative interaction with
miR-34c-5p (Fig. 2A and B). GABA is themost important inhibitory neu-
rotransmitter in the nervous system, leading to hyperpolarization of
neuronal membranes through GABAA receptors, which are chloride
channels comprising a pentameric subunit protein structure. In SGZ,
GABA is also involved in the control of the number of actively proliferat-
ing neural stem cells (NSCs) during neurogenesis via GABAergic inter-
neurons (Masiulis et al., 2011). Interestingly, GABAA receptor subunit
3 as well as GABBR2 were found to be expressed at lower levels in
leukocytes of patients with migraines compared to healthy controls
Fig. 5.A: Time-dependent Sox11mRNA expression after transfection of neonatal rat neuronswith anti-miR-132-3p or anti-miR-212-3p. Neonatal rat neurons were transfectedwith each
anti-miR (150 nM) alone and in combination and expression is normalized to neurons transfected with anti-miR-negative controls in respective concentrations (upper panel).
Immunoﬂuorescence microscopy images 96 hours after transfection of neonatal rat neurons with anti-miR-132 (150 nM) or anti-miR-212 (150 nM) or anti-miR-132 and anti-miR-212
(each 150 nM), anti-miR-negative control (150 nM) or anti-miR-negative control (300 nM) are shown. The green ﬂuorescent protein (GFP) expression vector pmaxGFP™was used as a trans-
fection control.Merged pictures show Sox11 protein (yellow signal) in anti-miR-transfected neurons. Arrows indicate intracellular Sox11 protein reservoirs (magniﬁcation: 400×). B: hsa-miR-
212-3p expression (mean ± SEM) in hippocampal and frontal cortical brain tissue from autopsies of individuals without neurological disease (n= 8) (upper panel) and in hippocampal and
temporal neocortical brain tissue of MTLE patients (n = 8) (array data). ** indicates p-values ≤ 0.01.
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with altered pharmacological treatment response of epilepsy patients
(Hung et al., 2013).
ADCY1 has not previously been identiﬁed as a target of hsa-miR-
212-3p (Fig. 2D). ADCY1 is mainly expressed in brain and plays a
major role in neuronal cAMP formation. Via NMDA-receptor binding,
calcium-inﬂux and calmodulin activation, glutamate postsynaptically
stimulates adenylate cyclase, thereby increasing intracellular cAMP
concentration and inducing expression of various CREB (cAMP responseelement-binding protein) dependent genes (Carlezon et al., 2005).
Those genes are involved in synaptic plasticity and in neurogenesis,
dendritic growth and arborization, a necessary requirement for correct
integration of newborn neurons (Nakagawa et al., 2002). However,
after abnormal stimulation of NMDA receptors through glutamate,
ADCY1 was reported to play a crucial role in neuronal excitotoxicity
(Wang et al., 2007). Taken together, down-regulation of the Gi protein
coupled receptors GRM7 and GABBR2 and a putative elevated expres-
sion of ADCY1 caused by the constellation of an increased expression
138 S. Haenisch et al. / Neurobiology of Disease 77 (2015) 127–140of hsa-miR-34c-5p and a decreased expression of hsa-miR-212-3p in
chronic epileptogenic brain tissue may lead to abnormal increases
in neuronal cAMP formation and neurogenesis, resulting in altered
plasticity and hyperexcitable neurons. This scenario could additionally
be strengthened by an altered functionality of GABAA receptors caused
by a decreased availability of subunit 3, which was identiﬁed as a target
of hsa-miR-34c-5p.
In this study we conﬁrm that MECP2, a methyl CpG binding protein
responsible for epigenetic control of neuronal gene expression, is a tar-
get of hsa-miR-212-3p (Im et al., 2010; Wada et al., 2010). Mutations
(Rett syndrome) and gene duplication (MECP2 duplication syndrome)
lead to severe impairment of neuronal development often accompanied
with epileptic seizures (Diaz de Leon-Guerrero et al., 2011; Na et al.,
2013; Ramocki et al., 2010). In adult neurogenesis, MECP2 was shown
to control the miR-137/Ezh2 axis involved in neural stem cell differen-
tiation (Szulwach et al., 2010).
In neurogenesis several neuronal transcription factors are sequen-
tially expressed and control stage-speciﬁc protein expression patterns
during proliferation, maturation and differentiation of newborn
neurons (Faigle and Song, 2013; Hodge et al., 2012). One of these tran-
scription factors is SOX11. The SOX protein family is classiﬁed in groups
(A-H), with SOX11 belonging to the SOX-C group (Kamachi and
Kondoh, 2013). To be functional, SOX proteins have to homo- or
heterodimerize with partner proteins, for example with transcription
factors belonging to the Pit-Oct-Unc (POU) or pairerd box (PAX) protein
families (Kamachi and Kondoh, 2013). There is evidence that members
of the SOX-B1 group (e.g. SOX2) initiate the expression of SOX-C group
members during neuronal fate commitment of precursor cells and neu-
ronal development (Bergsland et al., 2011). Moreover, it was shown
that the expression of SOX11 is strictly conﬁned to neuronally commit-
ted precursors and immature neurons, but is absent in mature neurons
(Haslinger et al., 2009; Mu et al., 2012).
In our investigation, SOX11 3′-UTR sequence showed the most
prominent interaction with hsa-miR-212-3p (Fig. 2C and D). Moreover,
in the SOX11-3′-UTR two differentmiR-212-3p binding siteswere iden-
tiﬁed. These sites were also targeted by hsa-miR-132-3p (Fig. 3). Both
miRNAs are transcribed from the same primary transcript and exhibit
identical seed sequences (Wanet et al., 2012). There was a clear inverse
overall correlation between Sox11 mRNA and both miR-212-3p and
miR-132-3p in neurons of neonatal rats. On closer inspection, however,
over the ﬁrst 48 hours an initial concurrent transcription of Sox11
mRNA and both miRNAs was observed. At 60 hours and later time
pointswhenmiR-212-3p andmiR-132-3phad reached a certain thresh-
old, Sox11 was strongly down-regulated (Fig. 4). Antagonizing both
miRNAs led to a clear attenuation of the time-dependent expression
pattern of Sox11. Sox11 mRNA and protein were highest in neurons
96 hours after co-transfection with both anti-miR-212-3p and anti-
miR-132-3p and these cells showed a less differentiated morphology
compared to controls. Cells transfected with anti-miR-132-3p showed
clear dendrite-like morphology, however, the dendrite structure was
less branched compared to control cells (Fig. 5). These ﬁndings are sup-
ported by two recent reports describing the role of miR-132 in length,
aborization, and integration of newborn neurons in the dentate gyrus
(Luikart et al., 2011; Magill et al., 2010). It may be speculated that
miR-132-3p is gradually more functionally relevant for arborization
and branching of newborn neurons than for controlling Sox11 expres-
sion. In contrast, collective ﬁndings of these studies further suggest
that miR-212-3p is predominantly involved in controlling Sox11 ex-
pression. It should be noted that the interference of miR-212-3p and
miR-132-3p with the 3′-UTR of the rat Sox11 homolog has not been
tested. However, an in silico analysis revealed a common binding site
for both miRNAs in the 3′-UTR of rat Sox11.
Since no SOX11 binding site was found in the 5′-UTR of rat and
human miR-212/132, the observed initial concurrent transcription of
SOX11 and miR-212/132 could be controlled through common tran-
scription factors. Candidate transcription factors include PAX3 andSP1; DR3 and E-Box (Enhancer box) sequences might also contribute
to this shared regulation. As mentioned above, members of the SOX-
B1 group (e.g. SOX2) can dimerize with proteins of POU and PAX fami-
lies in order to initiate the transcription of their downstream target
genes. The putative PAX3 binding site implies that not only members
of the SOX-C family, but also miR-212/132 could be included in those
target genes. The transcription factor binding site for SP1 and the E-
box sequence (e.g. c-Myc binds to E-box) are involved in chromatin re-
modeling and transcription initiation; DR3 response elements can bind
PXR (pregnane X receptor) /RXR (retinoid X receptor) or CAR (constitu-
tive androstane receptor)/RXR heterodimers (Handschin and Meyer,
2003). Since several anticonvulsants (e.g. carbamazepine, phenobarbi-
tal and phenytoin) are PXR/CAR ligands (Handschin and Meyer,
2003), an interesting question for future studies is whether these anti-
convulsants have a modifying effect on seizure-induced neurogenesis.
ABCG2 was identiﬁed as a weak target of miR-212-3p. Interaction
betweenmiRNA-212-3p and ABCG2was also demonstrated in an earli-
er study (Turrini et al., 2012). ABCG2 is an important efﬂux transporter
implicated in chemo-resistance of tumor stem cells (Mo and Zhang,
2012). Since it is also expressed at the blood brain barrier (Mo and
Zhang, 2012), ABCG2 may inﬂuence the distribution of anticonvulsants
in the central nervous system.Moreover, ABCG2 is also a stem cell factor
used to separate stem cells from their more differentiated progeny cells
(Mo and Zhang, 2012; Scharenberg et al., 2002). In the context of
neurogenesis, a miR-212-3p mediated parallel control of SOX11 and
ABCG2 may be involved in the maturation process of neuronal stem
cells into mature granule neurons through sequential expression of dis-
tinct protein markers.
Several limitations of the study have to be addressed. By usingwhole
hippocampal tissue sections, the possibility that the observed changes
in miRNA expression may also originate from or affect other cell popu-
lations (e.g. astrocytes, oligodendrocytes) than granule cells cannot be
completely excluded. It is also possible that some of the observed
epilepsy-induced altered miRNAs are part of a repair process as report-
ed earlier for miRNA-184 (McKiernan et al., 2012b). A reactive down-
regulation of miR-212-3p with an up-regulation of SOX11 may indicate
an attempt of forced neurogenesis, however, potentially accompanied
by impaired neuronal differentiation or even increased production of
astrocytes due to altered neuronal fate decision (Crespel et al., 2005;
Hattiangady and Shetty, 2008; Kralic et al., 2005; Kuruba et al., 2009).
Another critical point is the choice of control tissue. By comparing hip-
pocampus and temporal neocortex it is difﬁcult to distinguish between
natural tissue-speciﬁc differences in miRNA expression and epilepsy-
mediated differences. Recent investigations of Ziats and Rennert, how-
ever, uncovered a relatively small set of 30 miRNAs differentially
expressed between cortical (prefrontal cortex) and hippocampal tissue
in healthy adolescents (Ziats and Rennert, 2014). None of the dysregu-
lated miRNAs observed in our study was amongst these candidates,
whereas some of the identiﬁed miRNAs, as mentioned above, show
disease-dependent alterations in other epilepsy-models (Bot et al.,
2013; Hu et al., 2012; Kan et al., 2012; McKiernan et al., 2012b; Song
et al., 2011). Moreover, we did not observe a signiﬁcant difference in
hsa-miR-212-3p expression between hippocampal and frontal cortical
tissue from autopsies of individuals without neurological disease
(Fig. 5B), additionally supporting the idea, that at least someof the iden-
tiﬁed miRNAs (e.g. hsa-miR-212-3p) may indeed be disease-mediated
rather than tissue-dependently dysregualted. Although only a small
overlap in putative disease-mediated dysregualted miRNAs were seen
compared to other studies using normal hippocampus from autopsies
as control tissue (Kan et al., 2012;McKiernan et al., 2012a), notable sim-
ilarities were seen in the most highly expressed miRNAs in normal hip-
pocampus compared to temporal neocortex and hippocampus of MTLE
patients examined in this study (McKiernan et al., 2012a). Besides the
bias of tissue-speciﬁc differences in miRNA expression, one advantage
comparing hippocampal focal and temporal neocortical non-focal tissue
within a patient (as mostly done in this study) may be the exclusion of
Fig. 6. Proposed mechanism for how dysregulated miR-212-3p/132-3p expression could affect the time- and stage-speciﬁc expression of neuronal transcription factors during differen-
tiation andmaturation of newborn granule neurons in SGZ. (A)miR-212-3p/132-3p controls the stage-speciﬁc expression of Sox11during neuronalmaturation. (B)DeregulatedmiR-212-
3p/132-3p expression inMTLEmay lead to uncontrolled Sox11 expression andmay impair further differentiation of newborn neurons into mature granule neurons. Figure wasmodiﬁed
from (Bischofberger, 2007; Hodge et al., 2012). NCS: neural stem cells, INP: intermediate neuronal progenitors, GCL: granule cell layer, SGZ: subgranular zone.
139S. Haenisch et al. / Neurobiology of Disease 77 (2015) 127–140drug-induced alterations in miRNA expression, an important issue,
since several anticonvulsant drugs exhibit marked effects on gene ex-
pression. Future prospectively planned studies in larger cohorts involv-
ing collection of both temporal neocortical and hippocampal tissue of
normal brain is required to completely address these limitations.
Given that miR-212-3p is down-regulated in premature granule
cells in the chronic stage of MTLE, the resulting increase in SOX11 ex-
pression would halt the process of neurogenesis at the stage of imma-
ture neurons and would impair the ﬁnal maturation of neurons into
mature granule cells, supporting the suggestion of an impaired neuronal
differentiation in the chronic phase of epilepsy (Hattiangady and Shetty,
2008; Kuruba et al., 2009) (Fig. 6). Such a scenario could contribute to
impaired integration of newborn neurons into existing hippocampal
neural networks and altered excitability.
In conclusion, several target genes involved in neuronal signal trans-
mission, neuronal gene regulation, neuronal cAMP formation and drug
efﬂux were identiﬁed that may be altered through an epilepsy-
mediated differential hippocampal miRNA expression pattern. Future
studies should investigate whether these genes might serve as useful
targets to improve pharmacological therapy options for the treatment
of MTLE.
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